Indicative Announcement on Acceptance of Application for Drug Marketing Authorization
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference: View Attachment
Indicative Announcement on Acceptance of Application for Drug Marketing Authorization
Filed with SSE ·
On 6ix: 6ix.com/news/indicative-announcement-on-acceptance-of-application-for-drug-marketing-authorization
6ix hasn’t read this filing yet.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. on 6ix
Earlier from Jiangsu Hengrui Pharmaceuticals
- Announcement on Election of Employee Representative Directors for the 10th Board of Directors
- Indicative Announcement on Acceptance of Application for Drug Marketing Authorization and Inclusion into the Priority Review Program
- Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide
- Announcement on FDA Acceptance for Review of the Resubmitted Biologics License Application for Camrelizumab for Injection
- Elevar Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for Rivoceranib in Combination with Camrelizumab as a First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma
Later from Jiangsu Hengrui Pharmaceuticals
- Hengrui Pharma Announces Strong 2025 Annual Results
- Announcement on Convening the 2025 Annual Performance and Cash Dividend Briefing
- Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy
- Announcement on Completion of Unlocking the Lockup Period of Employee Stock Ownership Plan
- Announcement on Resolutions of the 1st Meeting of the 10th Board of Directors
Follow Jiangsu Hengrui Pharmaceuticals into a list and get an email when it puts out news.
Follow Jiangsu Hengrui Pharmaceuticals